Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cordlife Group ( (SG:P8A) ) just unveiled an announcement.
Cordlife Group Limited has received a notice from the Ministry of Health (MOH) regarding regulatory action affecting its cord blood banking service licence. The MOH has decided to modify the conditions of Cordlife’s licence, following the company’s submission of written representations. This regulatory update comes after a series of investigations and assessments related to the company’s operations, including the voluntary stoppage of new cord blood unit collections. The implications of this regulatory action may impact Cordlife’s ability to continue its services as previously structured, potentially affecting its market position and stakeholder interests.
The most recent analyst rating on (SG:P8A) stock is a Hold with a S$0.16 price target. To see the full list of analyst forecasts on Cordlife Group stock, see the SG:P8A Stock Forecast page.
More about Cordlife Group
Cordlife Group Limited is a company registered in Singapore, operating in the healthcare industry. It specializes in cord blood banking and human tissue banking services, focusing on the collection, testing, processing, and storage of cord blood units.
YTD Price Performance: 6.67%
Average Trading Volume: 42,907
Technical Sentiment Signal: Strong Sell
Current Market Cap: S$40.85M
For detailed information about P8A stock, go to TipRanks’ Stock Analysis page.